Journal article
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
BE Sands, FH Anderson, CN Bernstein, WY Chey, BG Feagan, RN Fedorak, MA Kamm, JR Korzenik, BA Lashner, JE Onken, D Rachmilewitz, P Rutgeerts, G Wild, DC Wolf, PA Marsters, SB Travers, MA Blank, SJ Van Deventer
New England Journal of Medicine | MASSACHUSETTS MEDICAL SOC/NEJM | Published : 2004
DOI: 10.1056/NEJMoa030815
Abstract
BACKGROUND: Infliximab, a monoclonal antibody against tumor necrosis factor, is an effective maintenance therapy for patients with Crohn's disease without fistulas. It is not known whether infliximab is an effective maintenance therapy for patients with fistulas. METHODS: We performed a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy of infliximab maintenance therapy in 306 adult patients with Crohn's disease and one or more draining abdominal or perianal fistulas of at least three months' duration. Patients received 5 mg of infliximab per kilogram of body weight intravenously on weeks 0, 2, and 6. A total of 195 patients who had a response at weeks 1..
View full abstractGrants
Awarded by National Institute of Diabetes and Digestive and Kidney Diseases